Sign in
Taking people in United StatesNo phase

Studies skin germs in healthy people and in people with eczema

Looks at germs on the skin of healthy people and people with eczema.

Key facts

Who runs it
National Human Genome Research Institute (NHGRI)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Status
Recruiting
People taking part
530 people, planned
Started
22 Jan 2008
Type of study
Observational, 6 groups
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy volunteers and people with moderate to severe eczema (atopic dermatitis). It also looks for people with certain inherited immune disorders (HIES, WAS or DOCK8) to study skin microbes.

Age
Healthy adults 18-50 years; healthy children 2-18 years; people with eczema or the immune disorders 2-40 years (as stated in the summary).
Sex
Males and females can join.
Disease stage
Eczema group: confirmed atopic dermatitis, moderate to severe (SCORAD 25 or higher), with at least 1 affected elbow-crease or knee-crease area. Immune disorder groups: mutation-proven HIES, WAS or DOCK8 diagnosis, with or without eczema.
Earlier treatment
Eczema group: no oral antibiotics or oral steroids for at least 7 days before skin sampling. No topical steroids or calcineurin inhibitors for 7 days or more on the skin areas to be sampled. Immune disorder groups: no topical steroids and emollients, preferably for 7 days but at least 24 hours before sampling.
Biomarker or test result
Immune disorder groups need a diagnosis proven by a gene mutation test. No other marker is asked for.

Main reasons for not taking part

  • Treatment with an IND agent, ultraviolet light therapy, monoclonal antibodies or systemic immunosuppressants within 7 days or 5 half-lives (whichever is longer) of starting
  • Cancer treated with chemotherapy or radiation in the previous 6 months
  • Past bone marrow transplant or gene therapy
  • Healthy groups: asthma, other chronic skin disease, or an immune deficiency
  • Healthy groups: health care workers, people living in care facilities, shelters or prisons, or with frequent contact with laboratory animals

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Must have a primary care professional who will continue standard of care/evaluation in tandem with the protocol to whom information and recommendations can be communicated
  • Adult males or females aged 18-50 at time of enrollment
  • Confirmed diagnosis of AD (UK Working Party s Diagnostic Criteria)24
  • Moderate to severe AD SCORAD greater than or equal to 25(25)
  • Greater than or equal to 1 affected antecubital (or popliteal) fossae at time of enrollment to serve as a target site
  • Males or females 2-18 years of age
  • Must have mutation-proven diagnosis, with or without eczematous dermatitis

Who cannot take part

  • Any subjects receiving or planning to receive an IND agent, ultraviolet light therapy, monoclonal antibodies, or systemic immunosuppressants < 7 days or 5 half-lives (whichever is the longer time period) of initiating this protocol
  • Any subjects who have cancer, and are currently or have previously received treatment with chemotherapy or radiation for treatment of malignancies within the previous 6 months
  • Unable to remain off systemic (oral) antibiotics or systemic (oral) steroids for at least 7 days prior to body site sampling. Unable to temporarily discontinue use of topical steroids or calcineurin inhibitors for greater than or equal to 7 days to small areas of skin intended for sampling. (Topical therapies/emollients for AD may be continued to non-adjacent, nontarget sites.)
  • Unable to remain off topical steroids and emollients for preferably 7 days but at least 24 hours prior to body site sampling
  • Any subject with a history of bone marrow transplant or gene therapy
  • Underlying immunodeficiency, either as primary disease or secondary to treatment
  • Any subjects with unstable or uncontrolled or chronic medical conditions requiring treatment or hospitalization. Individual determinations will be made at the discretion of the medical investigator
  • Underlying immunodeficiency, either as primary disease or secondary to treatment
  • Other documented chronic dermatologic disease, such as AD or psoriasis that may interfere with evaluation of the cutaneous microbiome. Common transient conditions, such as acne, are permissible
  • Subjects who provide direct healthcare or reside in healthcare facilities or in non-hospital settings such as assisted living facilities, homeless shelters, jails and prisons as well as subjects with frequent exposure to laboratory animals
  • Any female with symptoms and/or serum hormone levels consistent with perimenopause
  • Subjects with asthma

Other criteria

  • INCLUSION CRITERIA:

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 100 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Heidi H Kong, M.D.Taking people

About the trial

What the trial wants to find out

This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.

Read full original descriptionShow less

Healthy volunteers, as well as patients with moderate to severe eczema (AD), between 2 and 40 years of age may be eligible for this study.

We also wish to enroll children and adults aged 2-40 who have been diagnosed with inherited immune disorders known as HIES (hyperimmunoglobulin-E syndrome), WAS (Wiskott-Aldrich syndrome), or DOCK8 immunodeficiency because they frequently have skin problems similar to AD.

Eligible participants undergo the following tests and procedures:

* Medical family and medication history * Skin examination * Blood tests (research blood as well as serum IgE, and complete blood count) * Skin samples to analyze microbes. Samples are obtained by the following methods: swabbing the skin with a cotton swab; scraping (scratching) the skin gently with a blade to remove only the outermost skin layers; and, only in adults, biopsy (surgical removal) of a small skin sample less than 1/4-inch (5 mm) in diameter. * Nose swabs to analyze microbes. * Patients with eczema may have photographs of their skin taken to help monitor the skin rashes.

Participants may be contacted periodically for follow-up studies. Patients with atopic dermatitis may have additional skin samples collected to examine changes in the skin bacteria over time and during all of the stages of eczema. In addition, patients who have a flare of their eczema are asked to undergo a skin sample collection as soon as possible.

The 6 groups in the trial

  • Grouo 3

    Healthy (pediatric) controls

  • Group 1

    Healthy (adult) volunteers

  • Group 2

    AD patients

  • Group 4

    Patients diagnosed with the primary immunodeficiency hyperIgE syndrome (HIES)

  • Group 5

    Patients diagnosed with the primary immunodeficiency Wiskott-Aldrich Syndrome (WAS)

  • Group 6

    Patients diagnosed with the combined immunodeficiency associated with DOCK8 mutation (DOCK8)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Studies of Skin Microflora in Healthy Individuals and Atopic Dermatitis Patients
Plain-language title
Studies skin germs in healthy people and in people with eczemaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT00605878, who can take part
Record updated
5 November 2026